ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

BridgeBio's Attruby surpasses expectations with booming Q1 revenue and strong market positioning. Read why BBIO stock is ...

There are many types of amyloidosis. Amvuttra (vutrisiran) is used to treat two kinds of amyloidosis. The first is known as hereditary transthyretin-mediated amyloidosis (hATTR) with ...

Morningstar brands and products Company Portfolio ...

Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin – – Additional 42-Month Data ...

“From the primary analysis of HELIOS-B, we know that AMVUTTRA profoundly impacts all-cause mortality, while preserving patients’ functional capacity and quality of ...

The recent approval and launch of Amvuttra for ATTR-CM represent a significant milestone for Alnylam. The drug received early approval with a broad label, which is considered a strong positive for ...

Alnylam Pharmaceuticals has shared positive new results from a late-stage trial of its RNAi therapeutic Amvuttra (vutrisiran) in transthyretin amyloid cardiomyopathy (ATTR-CM), an under-diagnosed and ...